Submitted by Anonymous (not verified) on 13 March 2024 - 15:44
Opinion/decision on a Paediatric investigation plan (PIP): Tavlesse, Fostamatinib, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Haematology-Hemostaseology;Immunology-Rheumatology-Transplantation, PIP number: P/0027/2022
Source: